Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stallergenes Greer Back On The M&A Beat

Executive Summary

A leading allergy company in Canada has been snapped up by Stallergenes Greer, targeting North America as part of a renewed business development strategy.

You may also be interested in...



Stallergenes Greer's Delisting To Focus Leadership On Facility Issues

The acquisition of the UK-headquartered leading allergy immunotherapy firm by its private majority shareholder is expected to remove the distraction of stock market listing obligations for management.

Stallergenes' Mite Allergy Results An Early Leaving Present For Retiring CEO

Positive Phase III data with its sublingual house dust allergy tablet heralds a likely increase in competition in the US allergy sector in the years to come and also provide an early leaving present for the company's retiring CEO.

Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC099587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel